BG104451A - Antiestrogen and progestin-containing peroral contraceptives - Google Patents

Antiestrogen and progestin-containing peroral contraceptives

Info

Publication number
BG104451A
BG104451A BG104451A BG10445100A BG104451A BG 104451 A BG104451 A BG 104451A BG 104451 A BG104451 A BG 104451A BG 10445100 A BG10445100 A BG 10445100A BG 104451 A BG104451 A BG 104451A
Authority
BG
Bulgaria
Prior art keywords
antiestrogen
progestin
peroral
contraceptives
neuterotrophic
Prior art date
Application number
BG104451A
Other languages
Bulgarian (bg)
English (en)
Inventor
Michael Gast
Christopher Miller
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of BG104451A publication Critical patent/BG104451A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG104451A 1997-11-06 2000-05-17 Antiestrogen and progestin-containing peroral contraceptives BG104451A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96508397A 1997-11-06 1997-11-06
PCT/US1998/023427 WO1999024027A2 (en) 1997-11-06 1998-11-04 Anti-estrogen plus progestin containing oral contraceptives

Publications (1)

Publication Number Publication Date
BG104451A true BG104451A (en) 2000-12-29

Family

ID=25509417

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104451A BG104451A (en) 1997-11-06 2000-05-17 Antiestrogen and progestin-containing peroral contraceptives

Country Status (28)

Country Link
EP (1) EP1051179B1 (hr)
JP (1) JP2001522798A (hr)
CN (1) CN1278732A (hr)
AR (1) AR016667A1 (hr)
AT (1) ATE304359T1 (hr)
AU (2) AU760540B2 (hr)
BG (1) BG104451A (hr)
BR (1) BR9813982A (hr)
CA (1) CA2307210A1 (hr)
CZ (1) CZ294155B6 (hr)
DE (1) DE69831605T2 (hr)
DK (1) DK1051179T3 (hr)
EA (1) EA200000492A1 (hr)
EE (1) EE04092B1 (hr)
ES (1) ES2246541T3 (hr)
GE (1) GEP20043290B (hr)
HR (1) HRP20000269A2 (hr)
HU (1) HUP0100293A3 (hr)
ID (1) ID24568A (hr)
IL (1) IL135621A0 (hr)
NO (1) NO20002167L (hr)
NZ (1) NZ503890A (hr)
PL (1) PL340623A1 (hr)
SK (1) SK6482000A3 (hr)
TR (1) TR200001268T2 (hr)
UA (1) UA68365C2 (hr)
WO (1) WO1999024027A2 (hr)
ZA (1) ZA9810136B (hr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120263A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to prevent bone loss-progesterone and estrogen agonists
NZ508200A (en) * 1998-05-15 2003-09-26 Wyeth Corp 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6380166B1 (en) 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
KR100653570B1 (ko) * 1999-09-13 2006-12-05 와이어쓰 2-(4-하이드록시-페닐)-1-[4-(2-아민-1-일-에톡시)-벤질]-1h-인돌-5-올의 글루코피라노시드 접합체
US6376486B1 (en) * 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
IL158871A0 (en) 2001-07-31 2004-05-12 Pfizer Prod Inc Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
AU2005302706B2 (en) * 2004-10-27 2011-12-15 Janssen Pharmaceutica N.V. Indole derivatives useful as progesterone receptor modulators
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
DE102008057230A1 (de) * 2008-11-11 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin
EA022551B1 (ru) 2010-06-10 2016-01-29 Серагон Фармасьютикалс, Инк. Модуляторы рецепторов эстрогена и их применение
CA2857057A1 (en) 2011-12-14 2013-06-20 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
DK3355884T3 (da) 2015-10-01 2021-08-02 Olema Pharmaceuticals Inc Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
CA3008020C (en) 2015-12-09 2024-02-20 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulators
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
RU2019102647A (ru) 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
JP7229162B2 (ja) 2017-01-06 2023-02-27 ジー1 セラピューティクス, インコーポレイテッド 癌の治療に対する併用療法
CN110461853A (zh) 2017-02-10 2019-11-15 G1治疗公司 苯并噻吩雌激素受体调节剂
BR112019027967A2 (pt) 2017-06-29 2020-07-14 G1 Therapeutics, Inc. forma b cristalina isolada, composição farmacêutica, método para o tratamento de um distúrbio, método de um composto ou composição, e, processo para produzir forma b cristalina.
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN DEGRADATION
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
WO2024097989A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein degraders
WO2024097980A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA716118B (en) * 1970-10-05 1972-05-31 Richardson Merrell Inc Contraception
ZA9510926B (en) * 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
IL120263A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to prevent bone loss-progesterone and estrogen agonists
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
ES2162198T3 (es) * 1996-04-19 2001-12-16 American Home Prod Agentes estrogenos.
US5747480A (en) * 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive

Also Published As

Publication number Publication date
EP1051179A2 (en) 2000-11-15
ZA9810136B (en) 2000-05-05
GEP20043290B (en) 2004-07-26
DE69831605D1 (de) 2005-10-20
AU760540B2 (en) 2003-05-15
PL340623A1 (en) 2001-02-12
CN1278732A (zh) 2001-01-03
WO1999024027A2 (en) 1999-05-20
NO20002167D0 (no) 2000-04-27
DE69831605T2 (de) 2006-06-14
HUP0100293A2 (hu) 2001-10-28
DK1051179T3 (da) 2005-10-31
CZ20001661A3 (cs) 2000-12-13
EE04092B1 (et) 2003-08-15
BR9813982A (pt) 2000-09-26
EP1051179B1 (en) 2005-09-14
IL135621A0 (en) 2001-05-20
ES2246541T3 (es) 2006-02-16
UA68365C2 (en) 2004-08-16
NZ503890A (en) 2002-08-28
HRP20000269A2 (en) 2000-12-31
CZ294155B6 (cs) 2004-10-13
NO20002167L (no) 2000-06-28
CA2307210A1 (en) 1999-05-20
TR200001268T2 (tr) 2001-01-22
ID24568A (id) 2000-07-27
AR016667A1 (es) 2001-07-25
SK6482000A3 (en) 2000-11-07
WO1999024027A3 (en) 1999-07-15
EE200000211A (et) 2001-04-16
AU1303199A (en) 1999-05-31
HUP0100293A3 (en) 2002-12-28
JP2001522798A (ja) 2001-11-20
AU2003204896B2 (en) 2006-06-15
ATE304359T1 (de) 2005-09-15
EA200000492A1 (ru) 2000-10-30

Similar Documents

Publication Publication Date Title
BG104451A (en) Antiestrogen and progestin-containing peroral contraceptives
NZ330741A (en) Contraceptive process and kit for female mammals, comprising a combination of gestagen and oestrogen
AU560487B2 (en) Contraceptive comprising gestodene and ethinylestradiol
FI915855A0 (fi) Matalaestrogeenisia oraalisia raskaudenehkäisyvalmisteita
DE69118494T2 (de) Kontrazeptionsverfahren und Schema
BG101553A (en) Progesterone antagonist and antiestrogenous active compounds of general application for female contraceptives
FI922206A (fi) Osmotisk, oral doseringsform foer fertilitets kontroll.
DE69710896D1 (en) Progestogen-anti-progestogen therapien
LU90341I2 (fr) 75 Ug de désogestrel en l'absence éthinyl oestradiol (cerazette)
NZ333750A (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
ATE91410T1 (de) Osmotische dosierungsform.
MX9707009A (es) Inyeccion de una vez al mes como un contraceptivo de base y para terapia de reemplazamiento hormonal para mujeres perimenopausicas y premenopausicas.